What is Acceleron Pharma's business focus and history?

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003 by Christoph Westphal, John Knopf, Mark Ptashne, Tom Maniatis, and Wylie Vale. It focuses on developing therapeutics for serious and rare diseases by targeting the TGF-beta superfamily of proteins. The company was acquired by Merck in November 2021 for $11.5 billion. Acceleron Pharma has developed products like REBLOZYL (luspatercept-aamt) and is advancing sotatercept for pulmonary arterial hypertension.

Acceleron Pharma Corporate Details & Core Services

Acceleron Pharma is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases, focusing on harnessing the power of the transforming growth factor (TGF)-beta superfamily of proteins.

Acceleron Pharma Contact Information & Official Links

Website https://www.acceleronpharma.com
Social    
Email id info@acceleronpharma.com
Phone number 617-649-9200
Head office address Cambridge, Massachusetts, United States
Tags Biotechnology Pharmaceuticals Rare Diseases

What are Acceleron Pharma's Key Business Metrics & Stats?

No of employees 312
Founded year 2003
Type private
Industry Biotechnology
Location Cambridge, Massachusetts, United States
Parent Company merck.com
Stock Name XLRN (NASDAQ)
Acceleron Pharma XLRN (NASDAQ) Firmographic Snapshot 2026 2003 Founded Year 312 Global Employees United States Headquarters Biotechnology Industry Private Type Verified by DexterAgent.ai

How much funding has Acceleron Pharma raised to date?

Name Description
Funding Amount USD 250 Thousand
Stage Seed
Latest Valuation 11.5 Billion (USD)
Lead Investor Polaris Venture Partners
Investors Polaris Venture Partners

What are Acceleron Pharma's Core Products?

Name Description
REBLOZYL (luspatercept-aamt) An erythroid maturation agent approved for the treatment of anemia in certain rare blood disorders.
Sotatercept A therapeutic candidate in Phase 3 development for the treatment of pulmonary arterial hypertension.

What are the latest developments at Acceleron Pharma?

Date Type Description
November, 2021 Acquisition Merck completed the acquisition of Acceleron Pharma for $11.5 billion.
Name Description
Legal Name Acceleron Pharma, Inc.
Cin number
GST number
Registration number

Who is in Acceleron Pharma's executive leadership team?

Name Designation
CEO Habib Dable
COO Steve Ertel
CMO Matt Sherman
CFO Kevin McLaughlin
Chairman Francois Nader

Where are Acceleron Pharma's primary office locations?

City Country
Cambridge United States

What are the current business signals and market intelligence for Acceleron Pharma?

Type of customer Healthcare Providers, Patients with Rare Diseases
Key customer domain

What is Acceleron Pharma's annual revenue history?

Year Revenue (USD)
2017 74.5 Million

What are Acceleron Pharma's risk management and compliance ratings?

GDPR RIsk No
Privacy Risk No
Company Ratings
Glassdoor Rating

What are Acceleron Pharma's business model and service classifications?

Saas No
Offline Stores No
Service No
Ecommerce No
Exporter No
Mobile App No
Retail No
B2B Yes
B2C No
Manufacturing Yes
Wholesale No
Importer No
Get Company Intelligence in API
(Price is 0.1 USD/Record - pay as you go)

 

Get Company Intelligence in API
(Price is 0.1 USD/Record - pay as you go)